Immunovant Inc logo

Immunovant Inc(IMVT)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
2-STAR RATING
PASS
LAST CLOSE
$34.18
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for IMVT

11/13/2026: IMVT (2-star) is currently NOT-A-BUY. Pass it for now.

Immunovant is a clinical-stage biotechnology company focused on developing innovative FcRn inhibitors for autoimmune diseases. Its main strength lies in a promising pipeline targeting the well-validated FcRn pathway with an emphasis on patient-friendly subcutaneous delivery. The primary growth story revolves around the potential for its next-generation molecule, IMVT-1402, to differentiate itself in a competitive market. However, the company faces high risks, including the absence of commercial revenue, significant execution hurdles in clinical trials, and intense competition from established large-cap biotech firms. It is best suited for growth-oriented investors with a high risk tolerance who are monitoring clinical data readouts and regulatory progress.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fit while signal remains positiveThe company is a classic clinical-stage biotech bet on disruptive innovation in the autoimmune space.
Momentum investorMixed fitMomentum is highly dependent on clinical trial results and regulatory news cycles.
Value investorWeak fitThere are no earnings or revenue to support traditional value-based valuation metrics.
Dividend investorWeak fitThe company is in an early growth phase and does not pay dividends.
Low-risk investorWeak fitThe inherent risk of binary clinical trial outcomes makes this unsuitable for low-risk portfolios.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighBiotech stocks often experience extreme swings based on clinical trial data releases.
Valuation riskHighValuation is based on speculative future cash flows from drugs not yet on the market.
Competition risk (FcRn market leaders)HighEstablished players have significant advantages in trial execution and commercial infrastructure.
Business qualityMediumThe company benefits from Roivant's platform, but the lack of commercialized revenue limits quality assessments.
Dividend incomeLow / noneNo dividend payments exist or are expected in the near future.
Execution riskHighThe success of the company rests entirely on the successful clinical development and regulatory approval of its pipeline.

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 7.07B USD
Price to earnings Ratio -
1Y Target Price 48.5
Price to earnings Ratio -
1Y Target Price 48.5
Volume (30-day avg) 1.5M shares
Beta 0.94
52 Weeks Range 21.86 - 45.42
Updated Date 11/15/2026
52 Weeks Range 21.86 - 45.42
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -2.56

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit 26.6%
Avg. Invested days 36
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
IMVT receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
IMVT has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and solid ownership. In FY2026 versus FY2025, growth and ownership metrics are mixed: negative earnings growth (-22.2%), soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
IMVT's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
IMVT's growth profile is soft, with the least-weak measure being revenue growth at +0.0% FY2026 versus FY2025. By comparison, while earnings growth (-22.2%, negative) and free-cash-flow growth (-8.1%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 55.4% and approximately 44.5% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 56.20% supports management-shareholder alignment.

Top 5 Institutional Investors

FMR Inc 7.96%
Deep Track Capital, LP 4.59%
BlackRock Inc 3.53%
Farallon Capital Management, L.L.C. 2.86%
Baker Bros Advisors LP 2.67%

Unit Economics (Per $1K Revenue)

★★★★★
IMVT generates approximately $-0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2026 results. Weak margins explain the 1-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -0.04% (Tax Credit)

Quantitative Style Profile

★★★★★
IMVT has a Short Squeeze Candidate profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Small / Mid Cap RiskShort Squeeze Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
Clinical DevelopmentDeveloping FcRn inhibitors to treat autoimmune diseases.The company currently makes no money; investors are funding development for potential future revenue.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 6.17B
Price to Sales(TTM) -
Enterprise Value 6.17B
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -14.12
Shares Outstanding 206.95M
Shares Floating 92.16M
Shares Outstanding 206.95M
Shares Floating 92.16M
Percent Insiders 56.2
Percent Institutions 55.44

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.